Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline


IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational

Chemed Corporation to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Chemed Corporation to Present at the 2021 RBC Capital Markets Global Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at approximately 10:20

Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

IMV Appoints Dr. Michael Kalos to Board of Directors: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Appoints Dr. Michael Kalos to Board of Directors


IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Dr. Michael

Merritt Hawkins Survey: New Physicians Getting Fewer Recruiting Offers
Merritt Hawkins Survey: New Physicians Getting Fewer Recruiting Offers


Physicians completing their training are getting fewer recruiting offers than in the past, most likely due to Covid-19, a new survey suggests. The survey also indicates that female physicians

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescentshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine

Hanger to Present at the BofA Securities 2021 Healthcare Conference
Hanger to Present at the BofA Securities 2021 Healthcare Conference


Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate in presentations

NanoString Technologies Releases Operating Results for First Quarter of 2021: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Releases Operating Results for First Quarter of 2021


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for

IMV’s Lead Immunotherapy to be Investigated in Breast Cancer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV’s Lead Immunotherapy to be Investigated in Breast Cancer


IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that The Lancet, an international, peer-reviewed medical journal, published the results of the

Puma Biotechnology Reports First Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports First Quarter 2021 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparisons are for the

AMN Healthcare Announces First Quarter 2021 Results
AMN Healthcare Announces First Quarter 2021 Results


AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2021 financial

Quidel Reports First Quarter 2021 Financial Results
Quidel Reports First Quarter 2021 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified

93rd Vifor Pharma Group Annual General Meeting: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
93rd Vifor Pharma Group Annual General Meeting


Regulatory News:



At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19

93. Generalversammlung der Vifor Pharma Gruppe: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
93. Generalversammlung der Vifor Pharma Gruppe


Regulatory News:



An der 93. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt. Angesichts der anhaltenden

Humana Healthy Horizons Invests $1.75 Million in No Kid Hungry to Address Food Insecurity for Kids and Families: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons Invests $1.75 Million in No Kid Hungry to Address Food Insecurity for Kids and Families


Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), today announces a new partnership with No Kid Hungry, a national campaign dedicated

TherapeuticsMD Announces First Quarter 2021 Financial Results
TherapeuticsMD Announces First Quarter 2021 Financial Results


TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021.



“I am pleased with our ongoing

Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Gameshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) to donate doses of the

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests
Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today a retail

Hanger Reports First Quarter 2021 Financial Results
Hanger Reports First Quarter 2021 Financial Results


Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the first quarter ended March 31, 2021

Xencor Reports First Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports First Quarter 2021 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported